The BD Veritor Plus System is already in use across Europe for detecting Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. Credit: BD.

Becton, Dickinson and Company (BD) has received an order from the Dutch Ministry of Health for 9.2 million of its SARS-CoV-2 antigen tests for use on the BD Veritor Plus System.

The rapid, point-of-care tests can detect the virus in symptomatic patients in approximately 15 minutes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

By the middle of this month, the first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor Plus System will be delivered to the Netherlands.

For improving testing capacity, the ministry increased the initial order by eight million.

BD expects to fulfil the delivery by June next year.

It marks the first government contract in Europe for the test, which was CE marked to the IVD Directive (98/79/EC) in September.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

BD Europe Integrated Diagnostic Solutions vice-president and general manager Fernand Goldblat said: “We’re proud to be working with the Dutch Ministry of Health to expand rapid testing for SARS-CoV-2.

“This rapid game-changing test is the latest effort in BD’s comprehensive response to address the world’s critical health needs during the global pandemic.”

BD Veritor Plus System is a portable, easy-to-use device and serves as an optimal fit for use in point-of-care settings.

The system is currently being used across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep.

In July, BD obtained the Food and Drug Administration (FDA) emergency use authorisation (EUA) for the SARS-CoV-2 antigen assay, making it available in the country.

BD also received a $24m investment from the US Government to support the manufacturing scale-up of Covid-19 diagnostic tests.

The US Department of Defense and the US Department of Health and Human Services made the investment.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact